Micardis and Foot deformity - a phase IV clinical study of FDA data

Summary:

Foot deformity is reported as a side effect among people who take Micardis (telmisartan), especially for people who are female, 50-59 old, also take Zometa, and have Bone density abnormal.

The phase IV clinical study analyzes which people have Foot deformity when taking Micardis. It is created by eHealthMe based on reports of 26,556 people who have side effects when taking Micardis from the FDA, and is updated regularly.

What is Micardis?

Micardis has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 27,605 Micardis users. Check the latest studies of Micardis.

What is Foot deformity?

Foot deformity (functional disability of foot) is found to be associated with 912 drugs and 705 conditions by eHealthMe. Check the latest studies of Foot deformity.

On Jul, 22, 2026

26,556 people reported to have side effects when taking Micardis.
Among them, 39 people (0.15%) have Foot deformity.

Among these 39 people:

What is the gender of people who have Foot deformity when taking Micardis? *

female: 73.68 %
male: 26.32 %

What is the age of people who have Foot deformity when taking Micardis? *

What are other drugs people take besides Micardis? *

What are other side effects people have besides Foot deformity? *

Gait Disturbance: 24 people, 61.54%
Pain: 23 people, 58.97%
Stress And Anxiety: 23 people, 58.97%
Oedema Peripheral (superficial swelling): 23 people, 58.97%
Fall: 23 people, 58.97%
Foot Fracture: 22 people, 56.41%
Pain In Extremity: 22 people, 56.41%
Acute Kidney Failure: 20 people, 51.28%
Insomnia (sleeplessness): 20 people, 51.28%
Abscess (pus): 20 people, 51.28%

What are the existing conditions these people have? *

Bone Density Abnormal: 16 people, 41.03%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 17.95%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 5 people, 12.82%
Diabetes: 5 people, 12.82%
Osteoporosis (bones weak and more likely to break): 5 people, 12.82%
Multiple Myeloma (cancer of the plasma cells): 5 people, 12.82%
Parkinson's Disease: 4 people, 10.26%
Insomnia (sleeplessness): 2 people, 5.13%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 5.13%
Infarction (obstruction of the blood supply to an organ or region of tissue): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Micardis and have Foot deformity?

- Check whether Foot deformity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Micardis:

Micardis (27,605 reports)

Foot deformity treatments and more:

Foot deformity (14,397 reports)

Browse all side effects of Micardis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Foot deformity:

Foot deformity (912 drugs)

Browse all the conditions that are associated with Foot deformity:

Foot deformity (705 conditions)

Related publications that referenced our studies

Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on telmisartan (the active ingredients of Micardis) and Micardis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.